Xenon Pharmaceuticals Inc. (FRA:XP0)
Germany · Delayed Price · Currency is EUR 38.20
+0.20 (0.53%)
At close: Nov 28, 2025
Xenon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 7.5 | - | - | 9.43 | 18.44 | 32.17 | Upgrade | |
Revenue Growth (YoY) | - | - | - | -48.83% | -42.68% | 371.02% | Upgrade |
Cost of Revenue | 272.71 | 210.39 | 167.51 | 105.77 | 75.46 | 50.52 | Upgrade |
Gross Profit | -265.21 | -210.39 | -167.51 | -96.33 | -57.03 | -18.36 | Upgrade |
Selling, General & Admin | 75.57 | 68.9 | 46.54 | 32.81 | 21.97 | 12.94 | Upgrade |
Operating Expenses | 75.57 | 68.9 | 46.54 | 32.81 | 21.97 | 12.94 | Upgrade |
Operating Income | -340.78 | -279.3 | -214.05 | -129.14 | -78.99 | -31.3 | Upgrade |
Interest Expense | - | - | - | - | - | -0.48 | Upgrade |
Interest & Investment Income | 30.91 | 41.94 | 27.62 | 8.71 | 0.47 | 2.28 | Upgrade |
Currency Exchange Gain (Loss) | 0.17 | -1.06 | 0.2 | -1.89 | 0.36 | 1.4 | Upgrade |
EBT Excluding Unusual Items | -309.7 | -238.42 | -186.24 | -122.32 | -78.17 | -28.11 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 3.55 | -2.93 | -0.72 | 0 | Upgrade |
Other Unusual Items | - | - | - | - | - | -0.99 | Upgrade |
Pretax Income | -309.7 | -238.42 | -182.69 | -125.26 | -78.89 | -29.09 | Upgrade |
Income Tax Expense | -3.37 | -4.09 | -0.29 | 0.12 | -0.01 | -0.26 | Upgrade |
Net Income | -306.33 | -234.33 | -182.39 | -125.37 | -78.88 | -28.84 | Upgrade |
Preferred Dividends & Other Adjustments | - | - | - | -0.44 | -1.8 | - | Upgrade |
Net Income to Common | -306.33 | -234.33 | -182.39 | -124.94 | -77.09 | -28.84 | Upgrade |
Shares Outstanding (Basic) | 79 | 78 | 67 | 61 | 44 | 36 | Upgrade |
Shares Outstanding (Diluted) | 79 | 78 | 67 | 61 | 44 | 36 | Upgrade |
Shares Change (YoY) | 4.00% | 16.45% | 10.48% | 38.77% | 21.09% | 23.57% | Upgrade |
EPS (Basic) | -3.89 | -3.01 | -2.73 | -2.06 | -1.77 | -0.80 | Upgrade |
EPS (Diluted) | -3.89 | -3.01 | -2.73 | -2.06 | -1.77 | -0.80 | Upgrade |
Free Cash Flow | -253.29 | -184.46 | -156.73 | -103.92 | -71.55 | -50.76 | Upgrade |
Free Cash Flow Per Share | -3.21 | -2.37 | -2.34 | -1.72 | -1.64 | -1.41 | Upgrade |
Gross Margin | - | - | - | - | - | -57.07% | Upgrade |
Operating Margin | -4543.73% | - | - | -1368.91% | -428.45% | -97.31% | Upgrade |
Profit Margin | -4084.45% | - | - | -1324.32% | -418.11% | -89.65% | Upgrade |
Free Cash Flow Margin | -3377.15% | - | - | -1101.57% | -388.09% | -157.81% | Upgrade |
EBITDA | -338.18 | -276.74 | -211.99 | -127.74 | -78.09 | -30.66 | Upgrade |
EBITDA Margin | - | - | - | - | - | -95.31% | Upgrade |
D&A For EBITDA | 2.6 | 2.56 | 2.06 | 1.41 | 0.91 | 0.64 | Upgrade |
EBIT | -340.78 | -279.3 | -214.05 | -129.14 | -78.99 | -31.3 | Upgrade |
EBIT Margin | - | - | - | - | - | -97.31% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.